Krystal's Q3: Platform Designation Adds Pipeline Leverage As Vyjuvek Scales (Rating Upgrade)Seeking Alpha • 11/03/25
Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 10/27/25
Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?Zacks Investment Research • 09/30/25
FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering SkinBenzinga • 09/15/25
Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/03/25
Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting UpdateSeeking Alpha • 08/22/25
Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung CancerGlobeNewsWire • 08/21/25
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 OutlookZacks Investment Research • 08/05/25
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/04/25
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 07/28/25
Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis BullosaGlobeNewsWire • 07/25/25
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the DécolletéGlobeNewsWire • 07/24/25
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock UpZacks Investment Research • 07/10/25
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic KeratitisGlobeNewsWire • 07/09/25
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III StudyZacks Investment Research • 06/25/25
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?Zacks Investment Research • 06/25/25
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis BullosaGlobeNewsWire • 06/24/25
Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?Zacks Investment Research • 06/05/25